Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonism

Shu-Qi Zhang,Faith Thomas,Justin Fang,Kathryn Austgen,Chad Cowan,G. Grant Welstead

DOI: https://doi.org/10.1101/2024.05.05.592600

2024-05-07

Abstract:Immunogenicity limits the persistence of off-the-shelf, allogeneic cell therapies and transplants. While ablation of human leukocyte antigen (HLA) removes most T cell and humoral alloreactivity, no solution has enabled universal protection against the resulting natural killer (NK) cell response. Here, we engineered Trans Antigen Signaling Receptors (TASR) as a new class of NK inhibitory ligands and discovered CD300a, a previously inaccessible receptor, as a functional target. CD300a TASR outperformed leading alternative strategies in focused screens, including CD47 and HLA-E, and was solely capable of universally protecting allogeneic T cells against a large human cohort (45/45 donors), spanning diverse demographics and NK cell phenotypes. A model allogeneic T cell therapy co-expressing an anti-CD19 Chimeric Antigen Receptor (CAR) and CD300a TASR, produced using multiplexed non-viral integration, exhibited enhanced B cell killing potency under allogeneic immune pressure. CD300 TASR represents a universal solution to NK alloreactivity, broadening the population that could be effectively treated by next-generation allogeneic cell therapies.

Immunology

What problem does this paper attempt to address?

The paper primarily addresses a key issue in allogeneic cell therapy: how to protect these cells from natural killer (NK) cell attacks. Specifically, the research team developed a new technology called CD300a Agonist Signal Receptor (CD300a TASR), which can universally protect allogeneic T cells lacking human leukocyte antigen (HLA) from NK cell-mediated rejection.

Key findings of the paper include:
1. **Discovery and Optimization of CD300a TASR**: Through a series of screening experiments, researchers identified CD300a TASR as a novel inhibitory ligand that can effectively prevent NK cells from attacking allogeneic T cells. Additionally, they further optimized the design of CD300a TASR to enhance its functionality.
2. **Broad Population Applicability**: In studies involving a large number of human donors (45/45), CD300a TASR was shown to universally protect allogeneic T cells from NK cell attacks, indicating its potential applicability to a wide patient population.
3. **Enhanced CAR-T Cell Efficacy**: By integrating CD300a TASR with anti-CD19 chimeric antigen receptor (CAR) into T cells, researchers found that this strategy not only enhanced the T cells' ability to kill B cells but also maintained this enhanced effect under allogeneic immune pressure.

In summary, this study proposes an innovative approach to overcome the issue of NK cell rejection in allogeneic cell therapy and demonstrates the potential of this method in improving the efficacy of allogeneic CAR-T cell treatments.